Religião e uso de drogas por adolescentes Religion and drug use by adolescents

INTRODUÇÃO: Estudos internacionais e nacionais mostram que a religiosidade é um modulador importante no consumo de álcool e drogas entre estudantes adolescentes. OBJETIVOS: verificar se diferentes variáveis da religiosidade influenciam o uso freqüente e/ou pesado de álcool e drogas entre estudantes de 1º e 2º graus. MÉTODOS: Estudo transversal com uma técnica de amostragem do tipo intencional. Foi utilizado um questionário anônimo de autopreenchimento. A amostra foi constituída por 2.287 estudantes de escolas públicas periféricas e centrais e escolas particulares da cidade de Campinas, SP, entrevistados no ano de 1998. As drogas estudadas foram: álcool, tabaco, solventes, medicamentos, maconha, cocaína e ecstasy. As variáveis independentes incluídas na análise de regressão logística foram: filiação religiosa, freqüência de ida ao culto/missa por mês, considerar-se pessoa religiosa e educação religiosa na infância. Para identificar como as variáveis de religiosidade influenciam o uso de álcool e drogas utilizaram-se análises bivariadas e a análise de regressão logística para resposta dicotômica. RESULTADOS: O uso pesado de pelo menos uma droga foi maior entre os estudantes que tiveram educação na infância sem religião. O uso no mês de cocaína e de "medicamentos para dar barato" foi maior nos estudantes que não tinham religião. O uso no mês de ecstasy e de "medicamentos para dar barato" foi maior nos estudantes que não tiveram educação religiosa na infância. CONCLUSÕES: Várias dimensões da religiosidade relacionam-se com o uso de drogas por adolescentes, com possível efeito inibidor. Particularmente interessante foi que uma maior educação religiosa na infância mostrou-se marcadamente importante em tal possível inibição.<br>INTRODUCTION: Many international studies show that religion is an important dimension modulating the use of alcohol and drugs by adolescents. OBJECTIVES: to determine which religious variables are associated to frequent or heavy use of alcohol, tobacco and drugs among adolescents in intermediate and high schools in Campinas, Brazil. METHODS: A cross-sectional study using a self-report anonymous questionnaire was administered to 2.287 students from a convenience sample of seven schools: five from central areas (two public and three private schools) and two public schools from the outskirts of the city, in 1998. The study analyzes data regarding the use of alcohol, tobacco, medicines, solvents, marijuana, cocaine and ecstasy. The religious variables included in the regression analysis were: religious affiliation, church attendance, self-assessed religiousness, and religious education in childhood. For the substances, nicotine, alcohol, marijuana, cocaine, ecstasy and "abuse of medicines" a logistic regression analysis for dicotomic answer was applied. RESULTS: The heavy use of at least one drug during the last month was more frequent among students that did not have a religious education during childhood. The use in the last month of cocaine, ecstasy and (abuse of) medicines was more frequent among those students that had no religion (cocaine and medicines) and that did not have a religious education during childhood (ecstasy and medicines). CONCLUSIONS: this study is consistent with previous investigations demonstrating a strong influence of religious variables over the use of drugs among adolescents. Interesting, it was found that no or weaker religious education during childhood was markedly associated with significant more use of drugs during adolescence

Ezetimibe added to statin therapy after acute coronary syndromes

BACKGROUND: Statin therapy reduces low-density lipoprotein (LDL) cholesterol levels and the risk of cardiovascular events, but whether the addition of ezetimibe, a nonstatin drug that reduces intestinal cholesterol absorption, can reduce the rate of cardiovascular events further is not known. METHODS: We conducted a double-blind, randomized trial involving 18,144 patients who had been hospitalized for an acute coronary syndrome within the preceding 10 days and had LDL cholesterol levels of 50 to 100 mg per deciliter (1.3 to 2.6 mmol per liter) if they were receiving lipid-lowering therapy or 50 to 125 mg per deciliter (1.3 to 3.2 mmol per liter) if they were not receiving lipid-lowering therapy. The combination of simvastatin (40 mg) and ezetimibe (10 mg) (simvastatin-ezetimibe) was compared with simvastatin (40 mg) and placebo (simvastatin monotherapy). The primary end point was a composite of cardiovascular death, nonfatal myocardial infarction, unstable angina requiring rehospitalization, coronary revascularization ( 6530 days after randomization), or nonfatal stroke. The median follow-up was 6 years. RESULTS: The median time-weighted average LDL cholesterol level during the study was 53.7 mg per deciliter (1.4 mmol per liter) in the simvastatin-ezetimibe group, as compared with 69.5 mg per deciliter (1.8 mmol per liter) in the simvastatin-monotherapy group (P<0.001). The Kaplan-Meier event rate for the primary end point at 7 years was 32.7% in the simvastatin-ezetimibe group, as compared with 34.7% in the simvastatin-monotherapy group (absolute risk difference, 2.0 percentage points; hazard ratio, 0.936; 95% confidence interval, 0.89 to 0.99; P = 0.016). Rates of pre-specified muscle, gallbladder, and hepatic adverse effects and cancer were similar in the two groups. CONCLUSIONS: When added to statin therapy, ezetimibe resulted in incremental lowering of LDL cholesterol levels and improved cardiovascular outcomes. Moreover, lowering LDL cholesterol to levels below previous targets provided additional benefit